Remarks: Bortezomib is the 26S proteasome in mammalian cells and reversible inhibitor of chymotrypsin-like activity, treatment of relapsed or refractory advanced non-small cell lung cancer (NSCLC) and effective.
None of the products will be supplied to countries in which this could be in conflict with the existing patents. However the final responsibility lies with the Buyer.